Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974916 | 0.81 | MAOB (0.41) | NR1H2SMN1; SMN2FFAR1CETP | |
| SCHEMBL17974911 | 0.73 | HTR7 (0.40) | PTPN5MCL1HTR7 | |
| SCHEMBL17974907 | 0.72 | PTPN5 (0.58) | PTPN5HTR7 | |
| SCHEMBL20724251 | 0.70 | PTPN5 (0.43) | PTPN5NR1H2PTGER4FFAR1HTR7 | |
| SCHEMBL17974909 | 0.67 | NR1H2 (0.44) | NR1H2NR1H3 | |
| SCHEMBL19765240 | 0.66 | MAOB (0.43) | SMN1; SMN2FFAR1CETP | |
| SCHEMBL19765247 | 0.66 | CETP (0.40) | CETP | |
| SCHEMBL17974819 | 0.64 | AKT1 (0.40) | — | |
| SCHEMBL17974974 | 0.63 | TSHR (0.52) | NR1H2 | |
| SCHEMBL17974910 | 0.63 | MKNK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | PTPN5 3893/4885MCL1 1905/4885NR1H2 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.